Instituto Medico Rio Cuarto (Site 0501)

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials

Phase

• Phase 32 trials

Status

• Completed2 trials

Lead sponsor

• Merck Sharp & Dohme LLC2 trials

Closed trials

• Completed

  Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

  NCT03976323· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

  NCT03976362· Phase 3· Merck Sharp & Dohme LLC· Source